Stock Sale, Buyback News

TUCKER, Ga.--(BUSINESS WIRE)--GMS Inc. (NYSE: GMS) (the “Company”), a leading North American specialty building products distributor, confirmed that it has received an unsolicited proposal from QXO, Inc. (“QXO”) to acquire all outstanding shares of GMS for $95.20 per share in cash. Consistent with its fiduciary duties and in consultation with its independent legal and financial advisors, the GMS Board of Directors will carefully review and evaluate the unsolicited proposal to determine the cour...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 1,116,000 shares of its common stock, consisting of stock options to purchase an aggregate of 744,000 shares of common stock, and restricted stock units (“RSUs”) representing an aggregate of 372,000 shares of common stock, to 16 newly hired employees as an inducement material to their acceptance of employm...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX) (“Quince” or the “Company”), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the closing of its previously announced sale and issuance to certain institutional and accredited investors, of its common stock (or pre-funded warrants in lieu thereof), and accompanying common warrants (“Warrants”) that resulted in ap...

WASHINGTON, Pa.--(BUSINESS WIRE)--CB Financial Services, Inc. (the “Company”) (NASDAQ: CBFV), the holding company for Community Bank, announced that its 5% common stock repurchase program was completed on June 13, 2025. The program commenced on July 26, 2024. In connection with the program, the Company purchased a total of 257,145 shares of the Company’s common stock at an average price of $28.70 per share. About CB Financial Services, Inc. CB Financial Services, Inc. is the bank holding compan...

TORONTO--(BUSINESS WIRE)--Dream Industrial REIT (TSX: DIR.UN) (the “Trust” or “Dream Industrial REIT”) announced today that it has priced a private placement of senior unsecured debentures (the "Offering") consisting of C$200 million aggregate principal amount of 4.287% Senior Unsecured Debentures, Series G maturing on July 3, 2030 (the "Series G Debentures"). In connection with the Offering, the Trust has entered into forward cross-currency interest rate swap arrangements to swap the proceeds...

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Venu Holding Corporation (“VENU” or the “Company”) (NYSE American: VENU), a developer, owner, and operator of upscale live music venues and premium hospitality destinations, today announced its recently launched, one-of-a-kind, Preferred Stock Offering can now be purchased through Traditional and Roth Individual Retirements Accounts (IRA) and Simplified Employee Pension plans (SEP). VENU’s Preferred Offering gives shareholders an opportunity to earn an...

NEW YORK & GURUGRAM, India--(BUSINESS WIRE)--MakeMyTrip Announces Pricing of Offering of US$1.25 billion 0.00% Convertible Senior Notes Due 2030....

NEW YORK & GURUGRAM, India--(BUSINESS WIRE)--MakeMyTrip Announces Upsize and Pricing of Primary Offering of Ordinary Shares....

HOUSTON--(BUSINESS WIRE)--Enterprise Products Partners L.P. (NYSE:EPD) (“Enterprise”) today announced that its operating subsidiary, Enterprise Products Operating LLC (“EPO”), has priced a public offering of $2.0 billion aggregate principal amount of notes comprised of (i) $500 million principal amount of senior notes due June 20, 2028 (“Senior Notes LLL”), (ii) $750 million principal amount of senior notes due January 15, 2031 (“Senior Notes MMM”), and (iii) $750 million principal amount of se...

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on June 16, 2025, it granted stock options to purchase an aggregate of 37,200 shares of common stock to two new...